Is BMRN a Buy or a Sell? The Bull and Bear Case (2026)
Last updated July 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases (BMRN) rests on Voxzogo growth engine: Voxzogo, for children with achondroplasia, generated roughly $920 million in 2025 and remains the primary growth driver, with most sales coming from outside the United States. The bear case rests on revenue is concentrated in a handful of products, so a setback for Voxzogo or a key enzyme therapy would weigh heavily on results. Analysts covering it publish targets from $50.00 to $120.00 against a $61.98 price, so even the professionals disagree by 80% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases, a niche where it has decades of experience. Its commercial base includes enzyme replacement therapies (Vimizim, Naglazyme, Palynziq and others) for lysosomal and metabolic disorders, plus Voxzogo, an injectable for children with achondroplasia that has become the company's fastest-growing product. In April 2026 BioMarin closed its roughly $4.8 billion all-cash acquisition of Amicus Therapeutics, adding Galafold for Fabry disease and the Pombiliti plus Opfolda regimen for Pompe disease to the portfolio. Separately, the company decided to withdraw its Roctavian hemophilia gene therapy from the market after failing to find a buyer, taking an asset write-down. The investment picture is one of steady, high-margin growth from a diversified set of rare-disease franchises rather than a single blockbuster bet. BioMarin generated about $3.2 billion of revenue in 2025 and has guided 2026 revenue to roughly $3.83 to $3.93 billion, an acceleration driven largely by the Amicus products and continued Voxzogo uptake. The bull case is durable pricing power, orphan-drug exclusivity, and Voxzogo label expansion; the bear case is heavy reliance on a few products, integration risk from the Amicus deal, and a valuation that already prices in growth.
The bull case: what would have to be true for $120.00
The most optimistic published target on BMRN is $120.00, +93.6% from the $61.98 price as of July 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Voxzogo growth engine
Voxzogo, for children with achondroplasia, generated roughly $920 million in 2025 and remains the primary growth driver, with most sales coming from outside the United States. BioMarin is pursuing label expansions and additional indications that could widen the addressable population. Continued patient additions are central to the company's raised 2026 outlook.
2. Amicus acquisition and portfolio breadth
The roughly $4.8 billion Amicus deal, completed in April 2026, added Galafold for Fabry disease and Pombiliti plus Opfolda for Pompe disease. Management expects the deal to be slightly dilutive to 2026 non-GAAP earnings but accretive starting in 2027. Successful integration diversifies revenue beyond the legacy enzyme therapies and Voxzogo.
3. Enzyme therapy base and margins
Established enzyme replacement products such as Vimizim, Naglazyme and Palynziq provide a stable, high-margin cash-generating base with long orphan-drug exclusivity. This recurring revenue funds research and the pipeline. Double-digit growth across enzyme therapies contributed to record 2025 revenue.
4. Pipeline optionality
BioMarin is advancing internal programs including BMN 333, BMN 351 and BMN 401, alongside further Voxzogo indications. These earlier-stage assets offer longer-term upside if trials read out well. The company has also shown willingness to prune assets, as with the Roctavian withdrawal, to focus resources.
The bear case: what would have to be true for $50.00
The most pessimistic published target is $50.00, -19.3% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases is worth if the risks below bite instead of the drivers above.
Revenue is concentrated in a handful of products, so a setback for Voxzogo or a key enzyme therapy would weigh heavily on results. Rare-disease pricing draws scrutiny from payers and governments, and much of Voxzogo's revenue comes from international markets subject to reimbursement pressure. Competition is emerging, including Ascendis Pharma's TransCon CNP in achondroplasia and multiple Fabry and Pompe therapies from larger rivals. The Amicus acquisition adds integration and execution risk, and the Roctavian withdrawal shows that expensive programs can fail commercially. The shares trade at a premium multiple, leaving little margin for disappointment.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding BMRN already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on BMRN
25 analysts cover BMRN, with an average target of $87.92 (+41.9% against $61.98) and a split of 19 buy, 6 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the BMRN forecast and price target page.
How is BMRN valued? (as of JULY 2026)
Snapshot for BMRN as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (2025): ~$3.2B
- 2026 revenue guidance: ~$3.83B to $3.93B
- Q1 2026 revenue: ~$766M
- Q1 2026 non-GAAP EPS: ~$0.76
- 2026 non-GAAP EPS guidance: ~$4.85 to $5.05
- Market cap: ~$11B
BioMarin posted record 2025 revenue of about $3.2 billion and raised its 2026 revenue guidance to roughly $3.83 to $3.93 billion after adding the Amicus products, implying around 20 percent growth at the midpoint. Non-GAAP EPS guidance for 2026 was trimmed slightly to about $4.85 to $5.05 to reflect near-term dilution from the acquisition. Reported trailing GAAP multiples look elevated versus biotech peers, so the story depends on the guided growth materializing.
How do you decide if BMRN is a buy?
Rather than asking whether BMRN is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold BMRN indirectly through an index or sector ETF before adding more.
What would change your mind on BMRN
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Voxzogo growth engine stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: revenue is concentrated in a handful of products, so a setback for Voxzogo or a key enzyme therapy would weigh heavily on results fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the BMRN stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about BMRN against your real portfolio and see your actual exposure before deciding.
Investing in BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases with AI
Connect the broker you already use and ask Walnut's AI how BMRN fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is BMRN a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Voxzogo growth engine, with revenue (2025) at ~$3.2B. The bear case rests on revenue is concentrated in a handful of products, so a setback for Voxzogo or a key enzyme therapy would weigh heavily on results. Analysts covering it are spread from $50.00 to $120.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell BMRN?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Revenue is concentrated in a handful of products, so a setback for Voxzogo or a key enzyme therapy would weigh heavily on results. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $50.00, -19.3% from the $61.98 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for BMRN?
+
Voxzogo growth engine. Voxzogo, for children with achondroplasia, generated roughly $920 million in 2025 and remains the primary growth driver, with most sales coming from outside the United States. The most optimistic analyst target on BMRN is $120.00, +93.6% from the $61.98 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for BMRN?
+
Revenue is concentrated in a handful of products, so a setback for Voxzogo or a key enzyme therapy would weigh heavily on results. Rare-disease pricing draws scrutiny from payers and governments, and much of Voxzogo's revenue comes from international markets subject to reimbursement pressure. Competition is emerging, including Ascendis Pharma's TransCon CNP in achondroplasia and multiple Fabry and Pompe therapies from larger rivals. The Amicus acquisition adds integration and execution risk, and the Roctavian withdrawal shows that expensive programs can fail commercially. The shares trade at a premium multiple, leaving little margin for disappointment. The most pessimistic published target is $50.00, -19.3% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases do?
+
BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases, a niche where it has decades of experience.
What would have to change for BMRN to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Voxzogo growth engine) stalling in the reported numbers rather than in the narrative, the risk above (revenue is concentrated in a handful of products, so a setback for Voxzogo or a key enzyme therapy would weigh heavily on results) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does BioMarin do?
+
BioMarin develops and commercializes therapies for rare genetic diseases. Its portfolio includes enzyme replacement therapies for lysosomal and metabolic disorders, Voxzogo for children with achondroplasia, and, following the 2026 Amicus acquisition, Galafold for Fabry disease and the Pombiliti plus Opfolda regimen for Pompe disease.
How do you invest in BMRN?
+
BMRN trades on the Nasdaq, so you can buy shares through any brokerage account, either as a standalone position or as part of a healthcare or rare-disease themed basket. Some investors also gain exposure indirectly through biotech and healthcare ETFs that hold the stock.
Is BMRN a good investment?
+
That depends on your goals, time horizon and risk tolerance, and Walnut is not an investment adviser. The descriptive picture is a profitable rare-disease specialist with accelerating revenue but concentrated product risk and a premium valuation, so it is worth weighing the growth drivers against the risks yourself or with a licensed adviser.
Walnut is informational, not investment advice, and gives no verdict on BMRN. Analyst targets referenced here come from a July 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.
Guides that feature BMRN
BMRN is one of the names covered in these guides. Each one puts the stock next to its peers so you can see where it fits rather than judging it alone.